^
    2ms
    Florida selects DiaCarta’s cfDNA Test (RadTox™) for statewide use to detect early response of cancer treatment (DiaCarta Press Release)
    "DiaCarta...announced that Florida Health Department selected 'using plasma DNA concentration (DiaCarta’s RadTox™ test) for early detection of treatment response and resistance' through the Casey DeSantis Florida Cancer Innovation Fund. This fund supports deployment of the RadTox™ test throughout the State of Florida to be performed between Radiotherapy or Chemotherapy doses for real time detection of treatment response or resistance. The results will be as a real time predictor of imaging data."
    Clinical data
    |
    RadTox™ Test
    3ms
    DiaCarta’s RadTox™ test to monitor tumor response receives Medicare coverage (DiaCarta Press Release)
    "DiaCarta...announced that its revolutionary RadTox™ test, designed for tumor response monitoring, is now eligible for reimbursement from Medicare, effective January 1, 2024."
    Medicare • Reimbursement
    |
    RadTox™ Test